What does the evidence say about Rosemary Cognitive Performance Meta-Analysis?

The current Migaku evidence database contains 2 reusable source documents for Rosemary Cognitive Performance Meta-Analysis. This answer focuses on benefits, uncertainty, and practical interpretation. - In the late-onset groups, the apolipoprotein E (APOE) gene, the strongest and most consistently replicated genetic risk factor, is associated with AD. [Lawal Rasheedat (2026); evidence level 3] - The ε4 allele increases the likelihood of developing AD and is associated with greater neuroinflammation and impaired lipid transport []. [Lawal Rasheedat (2026); evidence level 3] - 2 16 17 18 14 19 18 Although individuals with MCI face an elevated risk of progression to Alzheimer’s disease [,,], if not controlled properly [], the trajectories are highly variable. [Lawal Rasheedat (2026); evidence level 3] - 1 2 3 4 Alzheimer’s disease (AD) is the most common cause of dementia [], which accounts for 55.2 million dementia cases estimated globally and is projected to exceed 75.6 million cases by 2030 []. [Lawal Rasheedat (2026); evidence level 3] - This study consolidates the evidence based on phytochemicals for cognitive enhancement, highlighting a need for more robust, methodologically sound trials to determine if these natural compounds hold promise in cognitive therapeutics, particularly for populations with cognitive impairments. [Marsh Alexander (2026); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.